We have located links that may give you full text access.
In vitro and in vivo inhibitory effects of 6-hydroxyrubiadin on lipopolysaccharide-induced inflammation.
Immunopharmacology and Immunotoxicology 2017 June
Inflammation is a defensive response against a multitude of harmful stimuli and stress conditions such as tissue injury, and is one of the most common pathological processes of human diseases. 6-Hydroxyrubiadin, an anthraquinone isolated from Rubia cordifolia L., exhibits several bioactive properties. The aim of this study was to evaluate whether 6-hydroxyrubiadin can reduce the production of pro-inflammatory cytokines and ameliorate acute lung injury (ALI) in a mouse model. In this study, we demonstrated that 6-hydroxyrubiadin suppressed lipopolysaccharide (LPS)-induced nuclear factor-kappa B activation as well as the phosphorylation of c-Jun N-terminal kinase in RAW 264.7 macrophages. In addition, we also showed that 6-hydroxyrubiadin inhibited the expression of tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6 in phorbol myristate acetate (PMA)-primed U937 and RAW 264.7 cells. Furthermore, 6-hydroxyrubiadin treatment reduced the production of these cytokines in vivo and attenuated the severity of LPS-induced ALI. Thus, these results suggested that 6-hydroxyrubiadin may be a potential therapeutic candidate for the treatment of inflammation and inflammatory diseases.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app